BofA Securities initiated coverage on Aktis Oncology with a new price target
$AKTS
Biotechnology: Pharmaceutical Preparations
Health Care
BofA Securities initiated coverage of Aktis Oncology with a rating of Buy and set a new price target of $34.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/3/2026 | $30.00 | Overweight | Analyst |
| 2/3/2026 | $34.00 | Buy | BofA Securities |
| 2/3/2026 | $31.00 | Outperform | Leerink Partners |
| 2/3/2026 | Buy | TD Cowen | |
| 1/4/2024 | $2.00 → $1.00 | Overweight → Neutral | Piper Sandler |
| 9/6/2023 | $9.25 → $1.75 | Buy → Neutral | B. Riley Securities |
| 1/24/2023 | $9.25 | Buy | B. Riley Securities |
| 11/2/2021 | $18.00 → $13.00 | Outperform | Oppenheimer |
3 - Aktis Oncology, Inc. (0002035832) (Issuer)
4 - Aktis Oncology, Inc. (0002035832) (Issuer)
4 - Aktis Oncology, Inc. (0002035832) (Issuer)
SCHEDULE 13D - Aktis Oncology, Inc. (0002035832) (Subject)
SCHEDULE 13D - Aktis Oncology, Inc. (0002035832) (Subject)
SCHEDULE 13D - Aktis Oncology, Inc. (0002035832) (Subject)
4 - Aktis Oncology, Inc. (0002035832) (Issuer)
4 - Aktis Oncology, Inc. (0002035832) (Issuer)
4 - Aktis Oncology, Inc. (0002035832) (Issuer)
BOSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies, today announced that Matthew Roden, Ph.D., President and Chief Executive Officer of Aktis Oncology, will present at the following investor conferences in March 2026. TD Cowen 46th Annual Health Care Conference Date & Time: Tuesday, March 3, 2026, at 1:10 p.m. ETLocation: Boston, MA Leerink Partners Global Healthcare ConferenceDate & Time: Monday, March 9, 2026, at 1:40 p.m. ETLocation: Miami, FL A live w
U.S. FDA Fast Track designation granted to AKY-11891 for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have progressed on or after prior systemic therapiesOngoing Phase 1b trial of AKY-1189 enrolling patients with locally advanced or metastatic urothelial cancer and several other Nectin-4 expressing tumor types BOSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies, today announced that the U.S. Food and Drug Administ
BOSTON, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. ("Aktis"), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies, today announced the closing of its upsized initial public offering of 17,650,000 shares of its common stock, at an initial public offering price of $18.00 per share, occurred on January 12, 2026. In addition, the underwriters exercised in full their option to purchase an additional 2,647,500 shares of Aktis' common stock, at the initial public offering price of $18.00 per share. The sale of the 2,647,500 additi
Analyst initiated coverage of Aktis Oncology with a rating of Overweight and set a new price target of $30.00
BofA Securities initiated coverage of Aktis Oncology with a rating of Buy and set a new price target of $34.00
Leerink Partners initiated coverage of Aktis Oncology with a rating of Outperform and set a new price target of $31.00
Q3 Revenue Up 7% Quarter-Over-Quarter Filter-Related Revenue Up 13% Quarter-Over-Quarter, Third Highest in Company History Growth, Cost Savings Initiatives, CHIPS Act ITC Refund Support Operating Cash Flow Breakeven in Next Nine MonthsRobust Customer Activity in Wi-Fi AP, 5G Infrastructure, Defense, Timing Control, Semiconductor Back-End Services Company to Host Investor Update Call Today at 8:00 am ET Charlotte, N.C., May 13, 2024 (GLOBE NEWSWIRE) -- Akoustis Technologies, Inc. (NASDAQ:AKTS) ("Akoustis" or the "Company"), an integrated device manufacturer (IDM) of patented bulk acoustic wave (BAW) high-band RF filters for mobile and other wireless applications, t
Charlotte, N.C., May 07, 2024 (GLOBE NEWSWIRE) -- Akoustis Technologies, Inc. (NASDAQ:AKTS) ("Akoustis" or the "Company"), an integrated device manufacturer (IDM) of patented bulk acoustic wave (BAW) high-band RF filters for mobile and other wireless applications, will webcast its Q3FY24 results on Monday, May 13, 2024, at 8:00 am Eastern Time. Management will host a question-and-answer session at the end of the call. To listen to the call by telephone, please dial 877-407-3982 (domestic) or 201-493-6780 (international). The conference call will be webcast live on the Company's website and will be available for playback at the following URL: https://ir.akoustis.com/news-events/ir-calendar
Q2 Revenue Up 20% Year-Over-Year, In-Line with Prior Guidance Guiding Record Quarterly Revenue for the March Quarter—Up 18 to 25% SequentiallyGrowth, Cost Savings Initiatives, CHIPS Act ITC Refund Support Operating Cash Flow Breakeven in December QuarterRobust Customer Activity in Wi-Fi AP, 5G Infrastructure, Defense, Timing Control, Semiconductor Back-End Services Company to Host Investor Update Call Today at 8:00 am ET Charlotte, N.C., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Akoustis Technologies, Inc. (NASDAQ:AKTS) ("Akoustis" or the "Company"), an integrated device manufacturer (IDM) of patented bulk acoustic wave (BAW) high-band RF filters for mobile and other wireless applications, t
Charlotte, NC, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Akoustis Announces Leadership Transition Charlotte, NC, August 8, 2024 (GLOBE NEWSWIRE) - Akoustis Technologies, Inc. (Nasdaq: AKTS) ("Akoustis" or the "Company"), an integrated device manufacturer (IDM) of patented bulk acoustic wave (BAW) high-band RF filters for mobile and other wireless applications, announced today the mutually agreed resignation of Jeffery B. Shealy as Chief Executive Officer and as a member of the Board of Directors, effective August 6, 2024. Kamran Cheema, the Company's Chief Product Officer, will serve as interim Chief Executive Officer. Mr. Cheema has served as Chief Product Officer for the Company since 2022
Charlotte, N.C., March 23, 2023 (GLOBE NEWSWIRE) -- Akoustis Technologies, Inc. (NASDAQ:AKTS) ("Akoustis" or the "Company"), an integrated device manufacturer (IDM) of patented bulk acoustic wave (BAW) high-band RF filters for mobile and other wireless applications, announced today that it has appointed Michelle L. Petock as a new member of its board of directors. The appointment brings the total number of board members to eight. Ms. Petock will serve on the Strategic Development Committee and the Audit Committee of the Company's board of directors. Jerry Neal, co-Chairman of the board, stated, "Ms. Petock is a welcome addition to our board given her extensive accomplishments in financ
Charlotte, N.C., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Akoustis Technologies, Inc. (NASDAQ:AKTS) ("Akoustis" or the "Company"), an integrated device manufacturer (IDM) of patented bulk acoustic wave (BAW) high-band RF filters for mobile and other wireless applications, announced the appointment of Ken Boller as Chief Financial Officer. Mr. Boller joined the Company in 2017 as Corporate Controller and has served in the role of Interim Chief Financial Officer since 2018. Mr. Boller will continue to operate out of the North Carolina headquarters of Akoustis and will continue to lead the finance team in the new position. Prior to Akoustis, he was a Regional Controller and Corporate Director of
SC 13G/A - Akoustis Technologies, Inc. (0001584754) (Subject)
SC 13G - Akoustis Technologies, Inc. (0001584754) (Subject)
SC 13G - Akoustis Technologies, Inc. (0001584754) (Subject)